DOI:
10.1055/s-00049561
South Asian Journal of Cancer
LinksClose Window
References
Ferrero JM, Hardy-Bessard AC, Capitain O. et al.
Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
Cancer 2016;
122 (20) 3119-3126
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.